Detailed Narrative
GLP-1 Franchise Dominance and Pipeline Expansion
Eli Lilly's incretin franchise, Mounjaro and Zepbound, continued its impressive performance, driving significant revenue growth and market share gains. Mounjaro became the U.S. market leader in total type 2 diabetes incretin prescriptions in July, while Zepbound captured two-thirds of the branded anti-obesity market. The company also reported positive Phase III data for orforglipron in obesity, positioning it as a potential oral GLP-1 alternative, and for tirzepatide in cardiovascular outcomes, reinforcing its broad therapeutic potential. These advancements underscore Lilly's leadership in the cardiometabolic space and its commitment to expanding treatment options.
Manufacturing Capacity Ramp-Up
To meet the surging demand for its incretin medicines, Lilly significantly ramped up its manufacturing capabilities. The company produced over 1.6 times the amount of salable incretin doses in the first half of 2025 compared to the first half of 2024, with a substantial contribution from its new Research Triangle Park facility. Management expects to further increase production to at least 1.8 times the H2 2024 levels in the second half of 2025 and plans to announce locations for two new U.S. manufacturing facilities later this quarter. This aggressive expansion aims to alleviate supply constraints and support global access.
Strategic Acquisitions and R&D Progress
Lilly bolstered its pipeline through strategic business development, acquiring SiteOne Therapeutics to enhance its pain portfolio with a clinical-stage non-opioid program, and Verve Therapeutics for genetic medicines targeting cardiovascular disease. The company also initiated new Phase I and Phase II trials for several molecules, including a glucose-sensing insulin and a next-generation triple agonist, while discontinuing some earlier-stage programs. This balanced approach reflects a focus on high-potential assets and efficient pipeline management.
Drug Pricing Reform and Direct-to-Consumer Model
Management addressed the ongoing drug pricing reform discussions, advocating for a rebalancing of pricing between the U.S. and Europe and highlighting the need to deflate the 'gross-to-net bubble' in the U.S. Lilly emphasized its direct-to-consumer model, LillyDirect, which offers discounted access to medicines like Zepbound (over 50% off list price) and aims to provide price transparency. This model serves as a hedge against coverage gaps and aligns with efforts to lower patient costs, particularly for chronic conditions like obesity.
Regional Performance and Product Uptake
U.S. revenue growth of 38% was driven by strong volume, though partially offset by an 8% price decline. International markets showed robust growth, with Europe up 77% in constant currency, Japan up 7%, and China up 19%, all primarily fueled by Mounjaro. Ebglyss continued strong performance in atopic dermatitis with nearly doubled total prescriptions since Q1, and Omvoh made progress in Crohn's disease. Verzenio maintained its leadership in early breast cancer, with global sales up 12%, and Kisunla saw steady launch trajectory in Alzheimer's with approvals in 13 countries outside the U.S.